期刊论文详细信息
BMC Cancer
Feasibility of intensity-modulated and image-guided radiotherapy for locally advanced esophageal cancer
Nam P Nguyen2  Siyoung Jang4  Jacqueline Vock8  Vincent Vinh-Hung9  Alexander Chi7  Paul Vos3  Judith Pugh1  Richard A Vo5  Misty Ceizyk4  Anand Desai6  Lexie Smith-Raymond4 
[1] Department of Pathology, University of Arizona, Tucson, AZ, USA
[2] Department of Radiation Oncology, Howard University Hospital, 2401 Georgia Avenue, N.W., Room 2055, Washington, DC 20060, USA
[3] Department of Biostatistics, East Carolina University, Greenville, NC, USA
[4] Department of Radiation Oncology, University of Arizona, Tucson, AZ, USA
[5] Department of Pediatry, University of Virginia, Charlottesville, VA, USA
[6] Department of Radiation Oncology, Akron City Hospital, Akron, OH, USA
[7] Department of Radiation Oncology, University of West Virginia, Morgantown, WV, USA
[8] Department of Radiation Oncology, Lindenhofspital, Bern, Switzerland
[9] Department of Radiation Oncology, University Hospitals of Geneva, Geneva, Switzerland
关键词: Normal tissue sparing;    Tomotherapy;    Esophageal cancer;   
Others  :  858892
DOI  :  10.1186/1471-2407-14-265
 received in 2013-01-31, accepted in 2014-04-14,  发布年份 2014
PDF
【 摘 要 】

Background

In this study the feasibility of intensity-modulated radiotherapy (IMRT) and tomotherapy-based image-guided radiotherapy (IGRT) for locally advanced esophageal cancer was assessed.

Methods

A retrospective study of ten patients with locally advanced esophageal cancer who underwent concurrent chemotherapy with IMRT (1) and IGRT (9) was conducted. The gross tumor volume was treated to a median dose of 70 Gy (62.4-75 Gy).

Results

At a median follow-up of 14 months (1-39 months), three patients developed local failures, six patients developed distant metastases, and complications occurred in two patients (1 tracheoesophageal fistula, 1 esophageal stricture requiring repeated dilatations). No patients developed grade 3-4 pneumonitis or cardiac complications.

Conclusions

IMRT and IGRT may be effective for the treatment of locally advanced esophageal cancer with acceptable complications.

【 授权许可】

   
2014 Nguyen et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20140724053412493.pdf 1858KB PDF download
87KB Image download
100KB Image download
【 图 表 】

【 参考文献 】
  • [1]Pottgen C, Stuchske M: Radiotherapy versus surgery within multimodality protocols for esophageal cancer- a meta-analysis of the randomized trials. Cancer Treat Rev 2012, 38:599-604.
  • [2]Van Hagen P, Hulsholf MCCM, van Lanschot JJB, Steyerberg EW, van Berge Henegouwen MI, Winjhoven BPL, Richel DJ, Nieuwenhuijen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, ten Kate FJW, Creemers JG, Punt CJA, Plukker JTM, Verheul HMW, Spillenaar EJ, van Dekken H, van den Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Renders JG, Tilanus HW, van der Gast A, for the Cross group: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012, 366:2074-2084.
  • [3]Cooper JS, Guo MD, Herskovic A, McDonald JS, Martenson JA, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL: Chemoradiotherapy of locally advanced esophageal cancer: long term follow-up of a prospective randomized trial (RTOG 85-01). Radiotherapy oncology group. JAMA 1999, 281:1623-1627.
  • [4]Al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, Cooper J, Byhardt R, Davis L, Emami B: Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997, 15:277-284.
  • [5]Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, Pezet T, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cell carcinoma of the esophagus. J Clin Oncol 2005, 23:2310-2317.
  • [6]Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Sieber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H: Chemoradiation with or without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005, 23:2310-2317.
  • [7]Han J, Zhu W, Yu C, Zhou X, Li T, Zhang X: Clinical study of concurrent chemoradiotherapy or radiotherapy alone for esophageal cancer patients with positive lymph nodes metastasis. Tumori 2012, 98:60-65.
  • [8]Nutting CM, Bedford JL, Cosgrove VP, Tait DM, Dearnaley DP, Webb S: A comparison of conformal and intensity-modulated techniques for esophageal radiotherapy. Radiother Oncol 2001, 61:157-163.
  • [9]Chandra A, Guerrero TM, Liu HH, Tucker SL, Liao Z, Wang X, Murshed H, Bonnen MD, Garg AK, Stevens CW, Chang JY, Jeter MD, Mohan R, Cox JD, Komaki R: Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol 2005, 77:247-253.
  • [10]Kole TP, Aghayere O, Kwah J, Yorke ED, Goodman KA: Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three dimensional conformal radiotherapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys 2011, 83:1580-1586.
  • [11]Lin SH, Wang L, Myles B, Thall PF, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z: Propensity score-based comparison of long-term outcomes with 3-D conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2012, 84:1078-1085.
  • [12]Chen YJ, Liu A, Han C, Tsai PT, Schultheiss TE, Pezner RD, Vora N, Lim D, Shibata S, Kernstine KH, Wong JY: Helical tomotherapy for radiotherapy in esophageal cancer: a preferred plan with better conformal target coverage and more homogeneous dose distribution. Med Dosimetry 2007, 32:166-171.
  • [13]Nguyen NP, Krafft SP, Vinh-Hung V, Vos P, Almeida F, Jang S, Ceizyk M, Desai A, Davis R, Hamilton R, Modarresifar H, Abraham D, Smith-Raymond L: Feasibility of tomotherapy to reduce normal lung and cardiac toxicity for distal esophageal cancer compared to three-dimensional radiotherapy. Radiother Oncol 2011, 101:438-442.
  • [14]Chen WJ, Kerstine KH, Shibata H, Lim D, Smith DD, Tang M, Liu A, Pezner RD, Wong JYC: Image-guided radiotherapy of esophageal cancer by helical tomotherapy: acute toxicity and preliminary clinical outcome. J Thor Dis 2009, 1:11-16.
  • [15]Geler M, Astner ST, Duma MN, Jacob V, Nieder C, Putzhammer J, Winkler C, Molls M, Gelnitz H: Dose-escalated simultaneous integrated boost treatment of prostate cancer patients via helical tomotherapy. Strahlenther Onkol 2012, 188:410-416.
  • [16]Simone CB, Ly D, Dan TD, Ondos J, Ning H, Belard A, O’Connell J, Miller RW, Simone NL: Comparison of intensity-modulated radiotherapy, adaptive radiotherapy for soft tissue changes during helical tomotherapy for head and neck cancer. Radiother Oncol 2011, 101:376-382.
  • [17]Duma MN, Kampfer S, Schuster T, Winkler C, Geinitz H: Adaptive radiotherapy for soft tissue changes during helical tomotherapy for head and neck cancer. Strahlenther Onkol 2012, 188:243-247.
  • [18]Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Havashi Y, Hofletter W, Komaki R, Liao Z, Ajani JA: Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer 2012, 118:2632-2640.
  • [19]Hart JP, McCurdy MR, Ezhil M, Wei W, Khan M, Luo D, Munden RF, Johnson VE, Guerrero TM: Radiation pneumonitis: correlation of toxicity with pulmonary metabolic radiation response. Int J Radiat Oncol Biol Phys 2008, 71:967-971.
  • [20]Semrau R, Herzoz SL, Vallbomer D, Kocher M, Holscher A, Muller RP: Radiotherapy in elderly patients with inoperable esophageal cancer. Is there a benefit? Strahlenther Onkol 2012, 188:226-234.
  • [21]Lee HK, Vaporciyan AA, Cox JD, Tucker SL, Putnan JB, Ajani JA, Liao Z, Swisher SG, Roth JA, Smythe WR, Walsh GL, Mohan R, Liu HH, Mooring D, Komaki R: Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys 2003, 57:1317-1322.
  • [22]Kumekawa Y, Kanedo K, Ito H, Kurahashi T, Konishi K, Katagiri A, Yamamoto T, Kuwahara M, Kubota Y, Muramoto T, Mizutani Y, Imawari M: Late toxicity in complete responses cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Gastroenterol 2006, 41:425-432.
  • [23]Morota M, Gomi K, Kozuka T, Chin K, Matsuura M, Oquchi M, Ito H, Yamashita T: Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys 2009, 75:122-128.
  • [24]La TH, Minn AY, Fisher GA, Ford JM, Kunz P, Goodman KA, Koong AC, Chang DT: Multimodality treatment with intensity modulated radiation therapy for esophageal cancer. Dis Esophagus 2010, 23:300-308.
  • [25]Nguyen NP, Krafft SP, Vos P, Vinh-Hung V, Ceizyk M, Jang S, Desai A, Abraham D, Ewell L, Watchman C, Hamilton R, Jo BH, Karlsson U, Smith-Raymond L: Feasibility of tomotherapy for graves’ opthalmopathy: Dosimetry comparison with conventional radiotherapy. Strahlenther Onkol 2011, 187:568-574.
  • [26]Nguyen NP, Vock J, Chi A, Vinh-Hung V, Dutta S, Ewell L, Jang S, Betz M, Almeida F, Miller M, Davis R, Sroka T, Vo RP, Karlsson U, Vos P: Impact of intensity-modulated and image-guided radiotherapy on elderly patients undergoing chemoradiation for locally advanced head and neck cancer. Strahlenth Onkol 2012, 188:677-683.
  • [27]Liu M, Shi X, Guo X, Yao W, Liu Y, Zhao K, Liang G: Long-term outcome of irradiation with or without chemotherapy for esophageal squamous cell carcinoma: a final report on a prospective trial. Radiat Oncol 2012, 12:142.
  • [28]Toita T, Ogawa K, Adachi G, Kakinohana Y, Nishikoramori Y, Iraha S, Utsunomiya T, Murayama S: Concurrent chemoradiotherapy for squamous cell carcinoma of thoracic esophagus: feasibility and outcome of large regional field and high dose external beam boost radiation. Jpn J Clin Oncol 2001, 31:375-381.
  • [29]Hurmuzlu M, Monge OR, Smaaland R, Viste A: High dose definitive concurrent chemoradiotherapy in non metastatic locally advanced esophageal carcinoma. Dis Esophagus 2010, 23:244-252.
  • [30]Welsh J, Palmer MB, Ajani JA, Liao Z, Swisher SG, Hofstetter WL, Allen PK, Settle SH, Gomez D, Likhacheva A, Cox JD, Komaki R: Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys 2012, 82:468-474.
  • [31]Zhu W, Zhou K, Yu C, Han J, Li T, Chen X: Efficacy analysis of simplified intensity-modulated radiotherapy with high or conventional dose and concurrent chemotherapy for patients with neck and upper thoracic esophageal carcinoma. Asian Pacific J Cancer Prev 2012, 13:803-807.
  • [32]Fokas E, Weiss C, Rodel C: The role of radiotherapy in the multimodal management of esophageal cancer. Dig Dis 2013, 31:30-37.
  文献评价指标  
  下载次数:16次 浏览次数:28次